(S (NP-SBJ (NN Peptide) (NN vaccination)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (VBN enhanced) (NN tumor) (NN growth))) (PP (IN through) (NP (JJ specific) (NN T-cell) (NN tolerance) (NN induction))))) (. .))
(S (NP-SBJ (NP (NN Vaccination)) (PP (IN with) (NP (NP (JJ synthetic) (NNS peptides)) (VP (VBG representing) (NP (NP (NP (JJ cytotoxic) (NN T) (NN lymphocyte)) (PRN (-LRB- -LRB-) (NP (NN CTL)) (-RRB- -RRB-))) (NNS epitopes)))))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ protective) (JJ CTL-mediated) (NN immunity)) (PP (IN against) (NP-COOD (NP (NNS tumors)) (CC or) (NP (NNS viruses)))))))) (. .))
(S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NP (NN vaccination)) (PP (IN with) (NP (NP (DT a) (NN CTL) (NN epitope)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NP (DT the) (JJ human) (NN adenovirus) (NN type) (CD 5) (NN E1A-region)) (PRN (-LRB- -LRB-) (NP (NN Ad5E1A234-243)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP-49 (WDT which)) (S (NP-SBJ (-NONE- *T*-49)) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (JJ tumor-eradicating) (NN CTL))))))))) (, ,)))) (VP (VP-COOD (VP (VBZ enhances) (NP (-NONE- *RNR*-50))) (CONJP (RB rather) (IN than)) (VP (VBZ inhibits) (NP (-NONE- *RNR*-50)))) (NP-50 (NP (DT the) (NN growth)) (PP (IN of) (NP (JJ Ad5E1A-expressing) (NNS tumors)))))))) (. .))
(S (NP-SBJ-51 (NP (DT This) (JJ adverse) (NN effect)) (PP (IN of) (NP (NN peptide) (NN vaccination)))) (VP-COOD (VP (VBD was) (ADVP-TMP (RB rapidly)) (VP (VBN evoked) (NP (-NONE- *-51)))) (, ,) (VP (VBD required) (NP (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NN peptide)))) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS micrograms)) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBD was) (VP (VBN achieved) (NP (-NONE- *-51)) (PP (IN by) (NP-LGS (NP (DT a) (NN mode)) (PP (IN of) (NP (NN peptide) (NN delivery))) (SBAR (WHNP-52 (WDT that)) (S (NP-SBJ (-NONE- *T*-52)) (VP (VBZ induces) (NP (JJ protective) (JJ T-cell-mediated) (NN immunity)) (PP (IN in) (NP (JJ other) (NNS models))))))))))) (. .))
(S (NP-SBJ-53 (JJ Ad5E1A-specific) (NN CTL) (NN activity)) (VP (MD could) (ADVP-TMP (RB no) (RB longer)) (VP (VB be) (VP (VBN isolated) (NP (-NONE- *-53)) (PP (IN from) (NP (NNS mice))) (PP-TMP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NN Ad5E1A-peptide))))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (NN tolerization)) (PP (IN of) (NP (JJ Ad5E1A-specific) (NN CTL) (NN activity)))) (VP (VBZ causes) (NP (DT the) (VBN enhanced) (NN tumor) (NN outgrowth)))))))))) (. .))
(S (PP (IN In) (NN contrast) (TO to) (NP (NN peptide) (NN vaccination))) (, ,) (NP-SBJ (NP (NN immunization)) (PP (IN with) (NP (NP (NN adenovirus)) (, ,) (VP (VBG expressing) (NP (NN Ad5E1A))) (, ,)))) (VP-COOD (VP (VBD induced) (NP (JJ Ad5E1A-specific) (NN immunity))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (NN outgrowth)) (PP (IN of) (NP (JJ Ad5E1A-expressing) (NNS tumors)))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN immunization)) (PP (IN with) (NP (JJ synthetic) (NNS peptides)))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (JJ anti-tumor) (NN CTL) (NNS responses)))))))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP (VBP are) (ADJP-PRD (JJ important) (PP (IN for) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (NP (JJ safe) (JJ peptide-based) (NNS vaccines)) (PP (IN against) (NP-COOD (NP (NNS tumors)) (, ,) (NP (JJ allogeneic) (NN organ) (NNS transplants)) (, ,) (CC and) (NP (JJ T-cell-mediated) (JJ autoimmune) (NNS diseases)))))))))) (. .))
